# US 2015/0174221 A1 · Systems, compositions, and methods for transplantation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0174221 A1
- Document ID: US20150174221A1
- Status: Published application
- Kind: A1
- Application number: 14/380,234
- Filed: 2013-02-21
- Published: 2015-06-25
- Earliest claimed: 2012-02-21
- Assignees: Cytonics Corporation
- Applicants: Cytonics Corporation
- Inventors: Lewis Hanna; John David Laughlin; Shawn Robert Browning
- Web page: https://patentgrep.com/patent/US20150174221A1

## CPC

- A61K 38/57: from animals; from humans {(A61K38/553, A61K38/556 take precedence)}
- A61K 35/16: Blood plasma; Blood serum (umbilical cord blood A61K35/51)
- A61K 35/19: Platelets; Megacaryocytes
- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61K 38/1722: {Plasma globulins, lactoglobulins}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61M 1/34: Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- C07K 14/81: Protease inhibitors
- C07K 14/8107: {Endopeptidase (E.C. 3.4.21-99) inhibitors}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Systems and methods for purification and concentration of autologous alpha-2-macroglobulin (A2M) from whole blood are provided. Also provided are diagnostic methods for identifying sites in the synovial joints, spine, tendons or ligaments for treatment of pain, degeneration, or inflammation with autologous A2M. Methods for utilizing autologous A2M in combination with other autologous treatments (e.g. platelets and other growth factors) are provided in addition to combinations with exogenous drugs or carriers. Also provided is a method of producing recombinant A2M wild type or variants thereof where the bait region was modified to enhance the inhibition characteristics of A2M and/or to prolong the half life of the protein in joints and spine disc or epidural space.

## Claims

### Claim at position 1

1-202. (canceled)

### Claim 203

A liquid composition comprising:
(a) An alpha-2-macroglobulin polypeptide (A2M) isolated from a biological sample from an individual mammal, wherein a concentration of the A2M is at least 1.1 times higher than a concentration of A2M in the biological sample, and
(b) plasma, bone marrow aspirate (BMA), or another body fluid from the biological sample from the mammal;
wherein the liquid composition is non-immunogenic to the mammal.

### Claim 204 (depends on 203)

The composition of claim 203, wherein the composition further comprises non-A2M proteins with a molecular weight higher than 500 kDa, wherein the non-A2M proteins with a molecular weight higher than 500 kDa are present at a concentration of at least 1.1 times higher than found in the biological sample from the mammal.

### Claim 205 (depends on 203)

The composition of claim 203, wherein the composition comprises an amount of molecules that is less than 90% of the amount of those molecules present in the biological sample the mammal, wherein the molecules have a molecular weight of 500 kDa or less.

### Claim 206 (depends on 205)

The composition of claim 205, wherein the molecules are selected from the group consisting of interleukins, tumor necrosis factors (TNFs), monocyte chemoattractant proteins (MCPs), macrophage inflammatory proteins (MIPs), tumor growth factors (TGFs), and matrix metalloproteases (MMPs), chemokines, immunomodulatory mediators, and combinations thereof.

### Claim 207 (depends on 203)

The composition of claim 203, wherein the biological sample is blood or BMA.

### Claim 208 (depends on 203)

The composition of claim 203, further comprising platelets.

### Claim 209 (depends on 203)

The composition of claim 203, wherein the composition is substantially free of cells and particles larger than 1 μm.

### Claim 210 (depends on 203)

The composition of claim 203, wherein the mammal is a human.

### Claim 211

A method comprising:
(a) passing a biological sample from a mammal through a filter, thereby separating the sample into a filtrate and a retentate; and
(b) collecting the retentate, wherein the retentate comprises
(i) a concentration of A2M that is at least 1.1 times higher than the concentration of A2M present in the biological sample from the mammal, and
(ii) plasma, BMA, or another body fluid from the biological sample;
wherein the composition is non-immunogenic to the mammal.

### Claim 212 (depends on 211)

The method of claim 211, wherein the biological sample comprises plasma, platelets, red blood cells, white blood cells, or a combination thereof.

### Claim 213 (depends on 211)

The method of claim 211, wherein the filter comprises a filter having a molecular weight cut-off of at most 500 kDa.

### Claim 214 (depends on 211)

The method of claim 211, wherein the method comprises removing red blood cells, white blood cells, or a combination thereof, from the biological sample before (a).

### Claim 215 (depends on 214)

The method of claim 214, wherein the method comprises removing platelets from the biological sample before (a).

### Claim 216 (depends on 214)

The method of claim 214, wherein the removing comprises centrifuging the biological sample, wherein a supernatant of the centrifuged biological sample is the biological sample of (a).

### Claim 217 (depends on 211)

The method of claim 211, wherein the flowing comprises removing red blood cells, white blood cells, platelets, or a combination thereof.

### Claim 218 (depends on 217)

The method of claim 217, wherein the filter comprises a filter having a pore size of at most 1 μm.

### Claim 219 (depends on 211)

The method of claim 211, wherein flowing comprises applying tangential force filtration, centrifugation, gravitational force, mechanical force, or any combination thereof.

### Claim 220 (depends on 211)

The method of claim 211, further comprising adding platelets to the retentate.

### Claim 221

A method of treating an injury or a disease or condition whose pathogenesis comprises protease activity comprising administering to a mammal in need thereof a composition, wherein the composition comprises
(a) a liquid composition comprising:
(i) A2M isolated from a biological sample from an individual mammal, wherein a concentration of the A2M is at least 1.1 times higher than a concentration of A2M in the biological sample, and
(ii) plasma, BMA, or another body fluid from the biological sample; wherein the liquid composition is non-immunogenic to the individual mammal; or
(b) a recombinant A2M comprising a non-natural bait that replaces a wild-type A2M bait region, wherein the recombinant A2M is characterized by at least a 10% enhanced inhibition of a protease compared an inhibition of the protease by an equivalent amount of a wild-type A2M, wherein the non-natural bait region comprises a recognition site for a protease that is not present in a wild-type A2M.

### Claim 222 (depends on 221)

The method of claim 221, wherein the disease or condition is selected from the group consisting of cancer, a degenerative disease, a traumatic disease, an inflammatory disease, a disease with a pathogenesis associated with protease activity, arthritis, inflammation, ligament injury, tendon injury, bone injury, cartilage degeneration, cartilage injury, an autoimmune disease, back pain, joint pain, joint degeneration, disc degeneration, spine degeneration, bone degeneration, and any combination thereof.

### Claim 223 (depends on 221)

The method of claim 221, wherein at least 10% of a protease activity or a proinflammatory activity of the mammal is inhibited.

### Claim 224 (depends on 221)

The method of claim 221, wherein fibronectin-aggrecan complex (FAC) formation is inhibited in the mammal.

### Claim 225 (depends on 221)

The method of claim 221, wherein the composition comprises an agent that inhibits FAC formation.

### Claim 226

A composition comprising a recombinant A2M comprising a non-natural bait that replaces a wild-type A2M bait region, wherein the recombinant A2M is characterized by at least a 10% enhanced inhibition of a protease compared an inhibition of the protease by an equivalent amount of a wild-type A2M, wherein the non-natural bait region comprises a recognition site for a protease that is not present in a wild-type A2M.

### Claim 227 (depends on 226)

The method of claim 226, wherein the non-natural bait region comprises a plurality of recognition sites for one or more proteases.

### Claim 228 (depends on 226)

The method of claim 226, wherein the recombinant A2M is characterized by at least a 10% enhanced inhibition of two or more different proteases compared to an inhibition of the two or more different proteases by an equivalent amount of a wild-type A2M.

### Claim 229 (depends on 226)

The method of claim 226, wherein the protease is selected from the group consisting of a serine protease, a threonine protease, a cysteine protease, an aspartate protease, a glutamic acid protease, a metalloprotease, and combinations thereof.

### Claim 230 (depends on 226)

The method of claim 226, wherein the protease is selected from the group consisting of matrix metalloprotease 1 (MMP1), MMP2, MMP3, MMP7, MMP8, MMP9, MMP10, MMP11, MMP12, MMP13, MMP14, MMP15, MMP16, MMP17, MMP18, MMP19, MMP20, MMP21, MMP23A, MMP23B, MMP24, MMP25, MMP26, MMP27, MMP28; A Disintegrin and Metalloproteinase with Thrombospondin Motifs protease 1 (ADAMTS1), ADAMTS2, ADAMTS3, ADAMTS4, ADAMTS5, ADAMTS6, ADAMTS7, ADAMTS8, ADAMTS9, ADAMTS10, ADAMTS12, ADAMTS13, ADAMTS14, ADAMTS15, ADAMTS16, ADAMTS17, ADAMTS18, ADAMTS19, ADAMTS20, chymotrypsin, trypsin, elastase, a compliment factor; a clotting factor, thrombin, plasmin, subtilisin, neprilysin, thermolysin, Pregnancy-associated plasma protein A; Bone morphogenetic protein 1, lysostaphin, insulin degrading enzyme, ZMPSTE24, acetylcholinesterase, and combinations thereof.
